[Skip to Content]
[Skip to Content Landing]
March 13, 1981

Rifampin Prophylaxis for Contacts of Haemophilus influenzae Type b Disease

Author Affiliations

From the Departments of Pediatrics (Dr Cox) and Medicine (Drs Trincher and Rissing), Medical College of Georgia, and Richmond County Health Department (Dr Patton), Augusta, Ga; Department of Pediatrics, Southwestern Medical School, Dallas (Dr McCracken); and the Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine and the Division of Infectious Diseases, St Louis Children's Hospital (Dr Granoff).

JAMA. 1981;245(10):1043-1045. doi:10.1001/jama.1981.03310350031018

Rifampin prophylaxis (20 mg/kg once daily for four days) was used in close contacts of children with Haemophilus influenzae type b (HIB) disease. Two hours after a dose, the concentration of rifampin in serum and saliva exceeded the minimum bactericidal concentrations of organisms obtained from four of the carriers. In both a randomized prospective and an open study, nasopharyngeal carriage was eradicated in 37 (95%) of 39 contacts. No cases of serious H influenzae disease occurred in four to six months of follow-up. At the dose and treatment schedule used, rifampin was safe and effective for eradication of HIB carriage.

(JAMA 1981;245:1043-1045)